NeuroOne Medical Technologies Corporation Common Stock (NMTC)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with whether a business earns consistent profits and produces cash. NeuroOne fails that test. In fiscal 2025, the year ended 2025-09-30, it reported revenue of $9.1M and net income of -$3.6M. That was better than fiscal 2024, when revenue was $3.5M and net income was -$12.3M, and fiscal 2023, when revenue was $2.0M and net income was -$11.9M. But the latest filed quarter, fiscal Q3 2026 ended 2026-06-30, still showed revenue of $2.0M and net income of -$2.0M. The company has a real product area - cEEG and sEEG recording and neuromodulation - but it is an 18-employee medical device firm with no demonstrated moat. FairStock's calculations at the 2026-10-13 close of $1.10 show a negative P/E of -1.13, P/B of 2.56, ROE of -124.66%, ROCE of -58.07%, and FCF yield of -71.5%. Trailing free cash flow was -$7.2M against a $10.0M market cap. The Piotroski F-Score is 3/9 and Altman Z-Score is -16.87, consistent with financial distress. Debt is low at D/E 0.05, but cash burn is the issue. The FairStock Score is 21/100. The Lynch category is none because it lost money in each of the last four years. Revenue is growing, but growth without profit or positive cash flow is not enough. At $1.10, the stock trades near the low end of its 52-week range of $0.96 to $6.12, but cheapness is illusory when intrinsic value is uncertain and cash is leaving the business. I would need evidence of durable profitability and self-funding operations before considering it a sound value.

In plain English: NeuroOne makes medical devices that help record brain signals and treat nerve and movement problems. The company is still small and losing money, though sales have started to grow. At $1.10 a share, the price does not look clearly cheap because the business has no profits and spends more cash than it brings in.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer